Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Developing novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …
Non-genetic mechanisms of therapeutic resistance in cancer
JC Marine, SJ Dawson, MA Dawson - Nature Reviews Cancer, 2020 - nature.com
Therapeutic resistance continues to be an indominable foe in our ambition for curative
cancer treatment. Recent insights into the molecular determinants of acquired treatment …
cancer treatment. Recent insights into the molecular determinants of acquired treatment …
NCCN guidelines® insights: Ovarian cancer, version 3.2022: Featured updates to the NCCN guidelines
DK Armstrong, RD Alvarez, FJ Backes… - Journal of the National …, 2022 - jnccn.org
Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the
United States, with less than half of patients living> 5 years following diagnosis. The NCCN …
United States, with less than half of patients living> 5 years following diagnosis. The NCCN …
The evolving translational potential of small extracellular vesicles in cancer
Cancer-derived extracellular vesicles (EVs) are regarded as having promising potential to
be used as therapeutics and disease biomarkers. Mechanistically, EVs have been shown to …
be used as therapeutics and disease biomarkers. Mechanistically, EVs have been shown to …
[HTML][HTML] Ovarian cancer mutational processes drive site-specific immune evasion
High-grade serous ovarian cancer (HGSOC) is an archetypal cancer of genomic instability,,–
patterned by distinct mutational processes,, tumour heterogeneity,–and intraperitoneal …
patterned by distinct mutational processes,, tumour heterogeneity,–and intraperitoneal …
A single-cell landscape of high-grade serous ovarian cancer
Malignant abdominal fluid (ascites) frequently develops in women with advanced high-
grade serous ovarian cancer (HGSOC) and is associated with drug resistance and a poor …
grade serous ovarian cancer (HGSOC) and is associated with drug resistance and a poor …
A view on drug resistance in cancer
The problem of resistance to therapy in cancer is multifaceted. Here we take a reductionist
approach to define and separate the key determinants of drug resistance, which include …
approach to define and separate the key determinants of drug resistance, which include …
[HTML][HTML] ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours …
The development of guidelines recommendations is one of the core activities of the
European Society for Medical Oncology (ESMO) and European Society of Gynaecologial …
European Society for Medical Oncology (ESMO) and European Society of Gynaecologial …
Epithelial ovarian cancer
Epithelial ovarian cancer generally presents at an advanced stage and is the most common
cause of gynaecological cancer death. Treatment requires expert multidisciplinary care …
cause of gynaecological cancer death. Treatment requires expert multidisciplinary care …
[HTML][HTML] Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label …
Background Low-grade serous carcinoma of the ovary or peritoneum is characterised by
MAPK pathway aberrations and its reduced sensitivity to chemotherapy relative to high …
MAPK pathway aberrations and its reduced sensitivity to chemotherapy relative to high …